Author: Suehara Yoshiyuki
Publisher: Springer Publishing Company
ISSN: 1341-9625
Source: International Journal of Clinical Oncology, Vol.16, Iss.2, 2011-04, pp. : 92-100
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Soft tissue sarcomas are a heterogeneous group of malignant mesenchymal tumors, and novel tumors biomarkers and therapeutic targets are required to achieve early diagnosis and optimize therapy for individual patients. Global protein expression studies, an approach known as “proteomics”, can offer important clues for understanding tumor biology that cannot be obtained by other approaches. Proteomic studies, such as two-dimensional difference gel electrophoresis (2D-DIGE) and mass spectrometry, have provided protein expression profiles of soft tissue tumors that can be used to develop novel diagnostic and therapeutic biomarkers and allow molecular classification of tumors. In this article, a brief description of the methodology will be provided, followed by a few examples of the recent proteomic studies that have generated new information for the diagnosis, classification and treatment of soft tissue tumors.
Related content
Chemotherapy of Soft Tissue Sarcoma
Acta Oncologica, Vol. 42, Iss. 1, 2003-01 ,pp. :
Hyperthermia in soft tissue sarcoma
By Lindner Lars
Current Treatment Options in Oncology, Vol. 12, Iss. 1, 2011-03 ,pp. :
Mutational analysis of p53 and PTEN in soft tissue sarcoma
Molecular Medicine Reports, Vol. 5, Iss. 2, 2012-01 ,pp. :
Post-irradiation Soft Tissue Sarcoma
By Bloechle C. Peiper M. Schwarz R. Schroeder S. Zornig C.
European Journal of Cancer, Vol. 31, Iss. 1, 1995-01 ,pp. :
Staging of Soft Tissue Sarcoma: What Is New?
Annals of Surgical Oncology, Vol. 15, Iss. 10, 2008-10 ,pp. :